Beta-catenin Antagonist ST316

**Semantic type:** Pharmacologic Substance

**Definition:** A peptide antagonist of beta-catenin, with potential antineoplastic activity. Upon administration, the beta-catenin antagonist ST316 targets and binds to beta-catenin, thereby preventing the interaction between beta-catenin and its co-activator B-cell CLL/lymphoma 9 protein (BCL9) and results in beta-catenin ubiquitin-mediated proteolysis. This inhibits Wnt/beta-catenin oncogenic pathway signaling by preventing the translocation of beta-catenin to the nucleus and preventing the transcription of Wnt target genes that regulate the proliferation, migration, invasion, and the metastatic potential of tumor cells, as well as genes regulating the immunosuppression of the tumor microenvironment (TME). This results in tumor cell death and a pro-inflammatory TME. Constitutive activation of the Wnt/beta-catenin signaling pathway plays a key role in promoting survival, proliferation, and migration in various tumor cell types. BCL9, a co-activator of beta-catenin’s transcriptional activity, is overexpressed in many tumors and facilitates beta-catenin’s nuclear localization.

**Synonyms:** - ST 316 - ST-316 - ST316